<DOC>
	<DOCNO>NCT01193062</DOCNO>
	<brief_summary>The primary purpose study evaluate effect PF-04995274 cerebrospinal fluid level soluble Amyloid precursor protein fragment Amyloid beta fragment follow single oral dose healthy volunteer . Safety tolerability PF-04995274 single dose administration healthy volunteer also assess part objective .</brief_summary>
	<brief_title>Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274</brief_title>
	<detailed_description>The purpose study evaluate effect PF-04995274 CSF level s-APP Abeta fragment follow single oral dose healthy volunteer</detailed_description>
	<criteria>For cohort , healthy male and/or female subject nonchildbearing potential age 18 55 year , inclusive . ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure heart rate measurement , 12 lead ECG clinical laboratory test ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Pregnant nursing woman ; woman childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics-pharmacodynamics</keyword>
	<keyword>cerebrospinal fluid</keyword>
	<keyword>serial sampling</keyword>
</DOC>